Oct 30, 2019

Lipitor is still churning out billions of dollars

Data: Company filings; Note: First nine months of 2019 shown; Chart: Naema Ahmed/Axios

Lipitor, the cholesterol-lowering medication that has become the gold standard of statins, continues to generate roughly $2 billion per year in sales for Pfizer, even though its patent expired eight years ago.

The big picture: Almost all of Pfizer's Lipitor sales now come from China and other emerging markets. But Lipitor's ability to remain a blockbuster drug, even with so many generic competitors that cost pennies per pill, shows how distorted the global pharmaceutical system can be.

By the numbers: Worldwide Lipitor sales peaked in 2006, at almost $13 billion, with more than 60% coming from the U.S.

  • After Lipitor's patent lapsed in late 2011, sales started declining precipitously in the U.S. as numerous generic atorvastatin pills hit the market.
  • But since 2014, annual sales have hovered around $2 billion thanks to the gigantic Chinese market.
  • Pfizer has frequently won bids to sell Lipitor in Chinese hospitals, "as they could more easily offer quality assurances for their higher-cost medicines," Bloomberg reported earlier this year.
  • But after losing a large hospital bid last year, Pfizer lowered Lipitor's price in China by 30% "in the hope patients would buy it privately," the Financial Times reported.

Between the lines: Lipitor is mostly bought overseas but holds a small pulse domestically. Pfizer is on pace to sell roughly $100 million of the statin in the U.S. this year.

  • That isn't a lot of money broadly speaking. But it still means patients, health insurance programs and taxpayers are paying upwards of $14 per Lipitor pill when generic equivalents cost less than a dime per pill.
  • Pfizer advertises a Lipitor coupon card for the uninsured and those with commercial insurance — the type of card that is outlawed in Medicare and Medicaid because it's viewed as a kickback.
  • Pfizer didn't immediately respond to questions.

The bottom line: Lipitor remains a global money-maker for Pfizer despite generic competition.

Go deeper: Generic drugs aren't always favored

Go deeper

Researchers criticize $225,000 annual price of Pfizer's new heart-failure drug

Illustration: Rebecca Zisser/Axios

Some of the researchers who helped develop a new heart-failure drug are criticizing its high price, Bloomberg reports.

The intrigue: Pfizer, which makes the drug, says that it's targeted at a small population, justifying the high price. But critics say that the condition isn't that rare, setting up Pfizer to reap in a fortune from the medication.

Go deeperArrowNov 20, 2019

Generics wait years for Medicare coverage

Adapted from The Association for Accessible Medicines analysis; Chart: Andrew Witherspoon/Axios

Medicare is taking years longer than private insurance to cover some generic drugs, meaning seniors could be paying more for their prescriptions, according to Access for Affordable Medicines, a lobbying group for the generic drug industry.

Between the lines: A 2017 policy change made the distinction between generics and brand-name drugs unclear, forcing the two types to compete within the same formulary tiers, Bloomberg notes.

Go deeperArrowNov 22, 2019

Generic drugmakers considering federal price-fixing settlement

A Teva plant in Israel. Photo: Menahem Kahana/AFP via Getty Images

Several companies that manufacture generic drugs are talking with the Department of Justice to avoid indictments for allegedly colluding to raise their prices. They would pay fines and admit that some allegations are true, Bloomberg reports.

The big picture: These potential "deferred prosecution agreements" would only cover the federal probe, not the state-led antitrust investigation, but it could shed light on any price fixing that occurred in the generic drug marketplace.

Keep ReadingArrowNov 25, 2019